4.7 Article

Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

期刊

JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 137, 期 1, 页码 18-25

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2016.08.022

关键词

-

资金

  1. Regeneron
  2. Sanofi
  3. MedImmune
  4. Celgene
  5. Stiefel/GlaxoSmithKline
  6. Celsus
  7. BMS
  8. Amgen
  9. Drais
  10. AbbVie
  11. Anacor
  12. AnaptysBio
  13. Dermira
  14. Galderma
  15. Glenmark
  16. LEO Pharma
  17. Novartis
  18. Pfizer
  19. Vitae
  20. Mitsubishi Tanabe
  21. Eli Lilly
  22. Janssen
  23. Bristol-Myers Squibb
  24. Merck
  25. Grants-in-Aid for Scientific Research [15H05790] Funding Source: KAKEN

向作者/读者索取更多资源

Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections. Associations with cardiovascular, neuropsychiatric, and malignant diseases were increasingly reported, but confirmation of their link with atopic dermatitis requires longitudinal studies. Given the possibility of atopic dermatitis-related systemic immune activation, future investigations of new interventions should concurrently examine the impact on these comorbidities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据